Video Experimental Relacionado
Updated: May 10, 2026
07:21
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
El inhibidor de la aldosterona sintasa mejora el daño de órganos inducido por la angiotensina II
Anette Fiebeler1, Jürg Nussberger, Erdenechimeg Shagdarsuren
1Medical Faculty of the Charité, HELIOS Klinikum-Berlin, Franz Volhard Clinic, Berlin, Germany. fiebeler@fvk-berlin.de
Circulation
|June 9, 2005
Resumen
Reducir la aldosterona inhibiendo el CYP11B2 o la adrenalectomía reduce significativamente el daño de órganos en ratas transgénicas. La aldosterona producida en las glándulas suprarrenales es la principal fuente de aldosterona cardíaca, destacando su papel en el daño inducido por Ang II.
Área de la Ciencia:
- Investigación cardiovascular Investigación en el ámbito cardiovascular.
- Endocrinología Endocrinología.
- Nefrología Nefrología.
Sus antecedentes:
- La aldosterona y la angiotensina (Ang) II contribuyen al daño de los órganos.
- La aldosterona se sintetiza principalmente en las glándulas suprarrenales a través de la aldosterona sintasa (CYP11B2), pero también se produce una síntesis cardíaca local.
- Investigar métodos para reducir la aldosterona es crucial para mitigar el daño de órganos.
Objetivo del estudio:
- Para probar si la inhibición de CYP11B2 o la realización de una adrenalectomía (ADX) mejora el daño de órganos.
- Para determinar en qué medida la aldosterona cardíaca local se origina en la glándula suprarrenal.
Principales métodos:
- Utilizó ratas transgénicas con sobreexpresión de la renina humana y los genes angiotensinógenos (dTGR).
- Se ha administrado un inhibidor de CYP11B2 (FAD286) o losartán para dTGR.
- Se realizó una adrenalectomía (ADX) en dTGR, y algunos recibieron dexametasona y sal.
Principales resultados:
- FAD286 redujo la mortalidad, la hipertrofia cardíaca, la albuminuria y la deposición de tejidos en dTGR.
- Losartan normalizó la presión arterial en el dTGR.
- ADX redujo significativamente la hipertrofia cardíaca, la albuminuria y la deposición de tejidos, lo que indica que la aldosterona suprarrenal es la principal fuente cardíaca.
Conclusiones:
- La aldosterona es fundamental en el daño de órganos inducido por Ang II.
- Tanto FAD286 como ADX reducen efectivamente los niveles de aldosterona circulante y cardíaca.
- La aldosterona producida en las glándulas suprarrenales es el principal contribuyente a los niveles cardíacos de aldosterona.
Videos de Conceptos Relacionados
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...